Enliven Therapeutics falls 6%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Enliven Therapeutics (ELVN.US) fell more than 6% during regular trading to $48.12.

The stock is up 7.68% over the past five sessions, up 14.02% over the past six months and up 213.18% year to date. It sits 22.79% below its 52-week high of US$62.32.

The Nasdaq Composite is up 3.97% over the past five sessions and up 8.77% year to date.

The company reported zero revenue for the third quarter of fiscal 2026, with its net loss widening due to increased research and development expenses.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.